46 results on '"Borghaei, Hossein"'
Search Results
2. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
3. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
4. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
5. Immunotherapy of cancer
6. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
7. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
8. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
9. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
10. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
11. To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
12. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
13. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
14. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
15. Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.
16. Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma.
17. PD.01.01 Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI).
18. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
19. Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC).
20. Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy.
21. Cancer therapy with engineered monoclonal antibodies.
22. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature
23. Factors Associated with Toxicity and Response to Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Indolent Non-Hodgkin's Lymphoma.
24. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
25. Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
26. MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer.
27. P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy: Topic: Phase II + NK.
28. MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G.
29. OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057.
30. P2.03a-044 Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy: Topic: Clinical Trials.
31. P2.03a-018 A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC: Topic: Clinical Trials.
32. OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012.
33. P2.03b-048 Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer: Topic: Biomarkers.
34. MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates.
35. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology.
36. P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.
37. Phase II Trial of Cetuximab (C225) in Combination with Monthly Carboplatin (Cb) and Weekly Paclitaxel (Pac) in Patients with Advanced NSCLC: Promising Early Results.
38. NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NONSMALL CELL LUNG CANCER (NSCLC).
39. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
40. Phase ii study of weekly docetaxel (Doc) and gemcitabine (Gem) in relapsed patients (Pts) with advanced, platinum-exposed non-small cell lung cancer (NSCLC).
41. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.
42. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H.
43. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
44. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
45. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
46. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.